abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

Author information

Buckley L1, Guyatt G2, Fink HA3, Cannon M4, Grossman J5, Hansen KE6, Humphrey MB7, Lane NE8, Magrey M9, Miller M10, Morrison L11, Rao M12, Byun Robinson A13, Saha S6, Wolver S14, Bannuru RR12, Vaysbrot E12, Osani M12, Turgunbaev M15, Miller AS15, McAlindon T12. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1095-1110. doi: 10.1002/acr.23279. Epub 2017 Jun 6.

Abstract

Author information

1 Yale University, New Haven, Connecticut.

2 McMaster University, Hamilton, Ontario, Canada.

3 Geriatric Research Education and Clinical Center, VA Health Care System, Minneapolis, Minnesota.

4 Arthritis Consultants of Tidewater, Virginia Beach, Virginia.

5 University of California, Los Angeles.

6 University of Wisconsin, Madison.

7 Oklahoma University Health Sciences Center, Oklahoma City.

8 University of California Davis, Sacramento.

9 Case Western Reserve University, MetroHealth System, Cleveland, Ohio.

10 Rheumatology Associates, Portland, Maine.

11 Duke University Medical Center, Durham, North Carolina.

12 Tufts Medical Center, Boston, Massachusetts.

13 Rainbow Babies and Children's Hospital, Cleveland, Ohio.

14 Virginia Commonwealth University, Richmond.

15 American College of Rheumatology, Atlanta, Georgia.

Erratum in • Erratum. [Arthritis Care Res (Hoboken). 2017]

Abstract

OBJECTIVE: To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis(GIOP).

METHODS: We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group consensus process to determine the final recommendations and grade their strength. The guideline addresses initial assessment and reassessment in patients beginning or continuing long-term (≥3 months) glucocorticoid (GC) treatment, as well as the relative benefits and harms of lifestyle modification and of calcium, vitamin D, bisphosphonate, raloxifene, teriparatide, and denosumab treatment in the general adult population receiving long-term GC treatment, as well as in special populations of long-term GC users.

RESULTS: Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D but switching from an oral bisphosphonate to another antifracture medication in adults in whom oral bisphosphonate treatment is not appropriate, and continuing oral bisphosphonate treatment or switching to another antifracture medication in adults who complete a planned oral bisphosphonate regimen but continue to receive GC treatment. Recommendations for special populations, including children, people with organ transplants, women of childbearing potential, and people receiving very high-dose GC treatment, are also made.

CONCLUSION: This guideline provides direction for clinicians and patients making treatment decisions. Clinicians and patients should use a shared decision-making process that accounts for patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.